Empagliflozin mitigates metabolic dysfunction-associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes.
Sarra SmatiThibaud SotinPerrine DenielSimon DucheixMichael JoubertLucie ArnaudSamy HadjadjBertrand CariouCédric Le MayXavier PrieurPublished in: Diabetes, obesity & metabolism (2024)